Substance use

and Mental Illness:

Exploring the Connection

Supervised by: Presented by:

Dr. Akash Kumar Mahato Harsha Baid,
Assistant Director and [Link]. Clinical Psychology
Head, AIPAS & AIBHAS, trainee, AIBHAS,
Amity University, Amity University, Date Presented:
Kolkata Kolkata September 19th, 2024
 01
Content
• Addiction: Deconstructing the terminology • Substance abuse as a risk factor and its
⚬ History comorbidity with Mood disorders
⚬ Key definitions in addiction
⚬ Major depressive disorder
• Diagnosis and Classification ⚬ Bipolar disorder
(ICD-10 and DSM 5) ⚬ Gender differences
⚬ Trauma and social determinants
⚬ Classes of substance
⚬ Substance related disorders • Substance abuse as a risk factor and its
⚬ Criteria for harmful use and dependence comorbidity with Cognitive impairment and
• Neurobiological Mechanisms in addiction executive functioning
⚬ Impairment mechanism
• Substance use and mental health outcomes ⚬ Comorbid illnesses & its intersection

• Substance abuse as a risk factor and its • Substance abuse as a risk factor and its
comorbidity with Psychosis comorbidity with Personality disorders
⚬ Substance-Induced Psychotic Disorder ⚬ Borderline personality disorder
⚬ Schizophrenia and substance use ⚬ Antisocial personality disorder
⚬ Trauma, social determinants and psychosis ⚬ Narcissistic Personality Disorder
⚬ Neurobiological Mechanisms and ⚬ Avoidant personality disorder
Integrated Treatment ⚬ Obsessive-Compulsive personality disorder
 02
Content
• Substance abuse as a risk factor and its • Assessment Plan for Substance Use and
comorbidity with Neurodegenerative Comorbid Mental Health Conditions
Diseases
⚬ Alzheimer’s Disease • Role of the Mental Status Examination (MSE) in
⚬ Parkinson’s Disease Assessing Substance Use and Mental Health
⚬ Huntington’s Disease Comorbidity
⚬ Amyotrophic Lateral Sclerosis
• Substance abuse as a risk factor and its
• Impact on the therapeutic process
comorbidity with Impulsive Behaviors in
Youngsters
⚬ Attention-Deficit/Hyperactivity Disorder • Clinical considerations
⚬ Conduct Disorder
⚬ Bipolar Disorder • Challenges in Integrating Mental Illness and
⚬ Impulse-Control Disorders Substance Use Treatment
⚬ Post-Traumatic Stress Disorder
⚬ Eating Disorders • Future Scope and Directions
⚬ Autism Spectrum Disorder
⚬ Schizotypal Personality Disorder • Endnote
⚬ Obsessive-Compulsive Disorder
 03
Addiction: Deconstructing
the Terminology
Addiction is a neuropsychological disorder characterized by the persistent and increased use of substances
or engagement in behaviors despite significant negative consequences. This condition leads to distress and
an overwhelming urge to continue the behavior, which results in both physical and mental deterioration
(Volkow, Koob, & McLellan, 2016). Repeated use of substances alters brain function, heightening cravings
and diminishing self-control, illustrating how addiction is fundamentally a brain disorder shaped by a
complex interplay of psychosocial and neurobiological factors (Koob & Volkow, 2010)

The terms "addiction" and "addictive behavior" encompass a variety of disorders and maladaptive habits.
In medical contexts, addiction is defined by intense urges and compulsions toward substances or behaviors
that provide sensory rewards, such as alcohol, drugs, gambling, or sex (American Psychiatric Association,
2013)

Some common signs of addiction include:

• Compulsive engagement in rewarding stimuli
• Preoccupation with substances or behaviors
• Continued use despite negative consequences
• Habits characterized by immediate gratification, with delayed deleterious effects
 04
History 5

Historically, the term "addict" has acquired a negative connotation, which perpetuates stigma and
frames addiction as a moral failing rather than a medical issue. This stigma can lead to a lack of
empathy, reduced support, and discrimination, often discouraging individuals from seeking help and
negatively impacting the quality of treatment (Kelly, Saitz, & Wakeman, 2016; Corrigan, Watson, & Barr,
2006). The terminology used influences policy and public health approaches, often resulting in punitive
measures instead of supportive interventions (Volkow et al., 2016).

In response to this issue, there is a growing movement toward using person-centered language, such as
"person with a substance use disorder," to reduce stigma and promote a more compassionate,
evidence-based approach to care (Kelly et al., 2016).
 05
Key Defintions in Addiction
Addictive drug :
Psychoactive substances that, with repeated use, are associated with significantly higher rates
of substance use disorders, largely due to the drug’s effect on the brain’s reward systems
(Koob & Volkow, 2010).

Cross-tolerance/Cross-dependence :
The ability of one drug to be substituted for another, with both producing the same
physiological and psychological effects (e.g., diazepam and barbiturates).

Tolerance :
A phenomenon in which a given dose of a drug produces a decreased effect after repeated
administration, requiring larger doses to achieve the original effect.

Misuse :
Similar to abuse, but usually applies to the improper use of drugs prescribed by physicians
(Volkow et al., 2016).
 06
Key Defintions in Addiction
Dependence :
The repeated use of a drug or chemical substance, with or without physical dependence. Physical
dependence refers to an altered physiologic state caused by repeated administration of a drug, where
cessation results in a specific withdrawal syndrome (World Health Organization, 1992)

Codependence:
Codependence refers to a dysfunctional emotional and behavioral pattern in relationships where one
person (often a family member or close partner) is affected by or attempts to control the substance
abuser’s behavior. Here it is more about rescuing the other

Enablers :
An enabler is someone whose actions unintentionally support or facilitate the continuation of the
substance abuse by shielding the addict from experiencing the natural consequences of their
behavior. Enablers typically engage in more tangible actions that directly support the substance
abuse.

Abuse :
The use of any drug, usually by self-administration, in a manner that deviates from approved social or
medical patterns (American Psychiatric Association, 2013)
 07
Key Defintions in Addiction
Intoxication :
A reversible syndrome caused by a specific substance (e.g., alcohol) that affects one or more
functions: memory, orientation, mood, judgment, and behavioral, social, or occupational functioning
(American Psychiatric Association, 2013).

Withdrawal :
A substance-specific syndrome occurring after stopping or reducing the amount of the drug or
substance used regularly over a prolonged period. This syndrome includes both physiological
symptoms and psychological changes, such as disturbances in thinking, feeling, and behavior
(Kosten & O’Connor, 2003).

Neuroadaptation :
Neurochemical or neurophysiologic changes in the body resulting from the repeated administration of a
drug. Neuroadaptation accounts for tolerance. It includes pharmacokinetic adaptation (the body's
metabolizing system adapting to the substance) and cellular or pharmacodynamic adaptation (the
nervous system functioning despite high substance levels) (Nestler, 2001).
 08
Diagnosis and Classification
The International Classification of Diseases, 10th Revision (ICD-10) and the Diagnostic and Statistical
Manual of Mental Disorders, 5th Edition (DSM-5) are two widely used systems for diagnosing mental health
and substance use disorders. Both provide criteria for identifying different types of addiction, though they
categorize and define these disorders somewhat differently.

DSM 5 ICD 10
• F10: Alcohol
• Alcohol
• F15: Other stimulants including caffeine (e.g.,
• Stimulants
• amphetamines)
Caffeine
• F12: Cannabinoids (e.g., marijuana)
• Cannabis
• Psychotic disorder
• Cocaine
• F16: Hallucinogens (e.g., LSD, MDMA)
• Hallucinogens (phencyclidine and other)
• F18: Volatile solvents (e.g., inhalants)
• Inhalants
• F17: Tobacco
• Tobacco
• F11: Opioids (e.g., heroin, morphine)
• Opioids
• F13: Sedatives or hypnotics
• Sedatives, hypnotics, or Anxiolytics
• (e.g., benzodiazepines)
Other
• F19: Multiple drug use
 09
Diagnosis and Classification
The DSM-5, published by the American Psychiatric Association (APA), categorizes addictions under
"Substance-Related and Addictive Disorders." It also introduces non-substance-related disorders,
reflecting the broader understanding of addictive behaviors. The ICD-10, published by the World Health
Organization (WHO), classifies addictions primarily under the category "Mental and Behavioral
Disorders due to Psychoactive Substance Use" (F10–F19). It also recognizes behavioral addictions
under separate categories

DSM 5 ICD 10
• Intoxication • Intoxication
• Use disorder • Harmful use
• Withdrawal • Dependence syndrome
• Delirium • Withdrawal state
• Psychotic disorders • Withdrawal state with delirium
• Neurocognitive disorder • Psychotic disorder
• Amnestic disorder • Amnestic syndrome
• Mood disorders • Amnestic and late-onset psychotic
• Anxiety disorders disorder
• Sexual dysfunctions • Other mental and behavioural disorders
• Sleep disorders *classified under related
psychiatric disorders
 10
Diagnosis and Classification
Criteria for harmful use and dependence (ICD-10)

Harmful use: (A) A pattern of psychoactive substance use that is causing damage to health;
the damage may be to physical or mental health.

Dependence: (A) Diagnosis of dependence should be made if three or more of the following
have been experienced or exhibited at some time during the last year.

1. A strong desire or sense of compulsion to take the substance.

[Link] culties in controlling substance-taking behaviour in terms of its onset, termination, or levels of
use.
[Link] withdrawal state when substance use has been ceased or been reduced, as evidenced
by either of the following: The characteristic withdrawal syndrome for the substance or use of the
same (or closely related) substance with the intention of relieving or avoidance withdrawal
symptoms.
[Link] of tolerance, such that increased doses of the psychoactive substance are required to
achieve effects originally produced by lower doses.
[Link] neglect of alternative pleasures or interests because of psychoactive substance use and
increased amount of time necessary to obtain or take the substance or to recover from its effects.
[Link] with substance use despite clear evidence of overtly harmful consequences (physical or
mental)
 11
Diagnosis and Classification
Criteria for substance use disorder (DSM-5)

DSM- 5 captures all the symptoms associated with harmful use and dependence in ICD- 10.
However, there is no separate category for ‘dependence’ in DSM- 5 and the extent of the substance
use disorder is decided by the number of symptoms endorsed out of a total of 11 (mild, 2– 3
symptoms; moderate, 4– 5 symptoms; severe, 6 or more symptoms).

The symptoms cover the following areas:

• Use of the substance in greater amounts and for longer than was initially intended, with
concomitant problems in cutting down use, often associated with craving.
• The substance and the energies needed to obtain it gradually take over more and more of the
person’s life despite the harm this causes to other interests, roles, activities, and relationships.
• Substance use continues despite knowledge of the harm being done to the physical and
psychological health of the person. This can include the physical safety of the person and/ or
that of others to whom the person owes responsibility.
• The presence of pharmacological tolerance and withdrawal symptoms
 12
Neurobiological Mechanisms
in Addiction
The neurobiological mechanisms of addiction involve dysregulation of the brain's mesolimbic dopamine
system, which is crucial for reward and reinforcement. Addictive substances and behaviors lead to
excessive dopamine release in the nucleus accumbens, forming a strong link between the stimulus and
pleasure. Repeated exposure results in neuroadaptive changes, such as tolerance—where the brain's
response to dopamine diminishes—and dependence—where normal functioning becomes reliant on the
stimulus.

Chronic addiction also affects the prefrontal cortex, impairing decision-making, impulse control, and
self-regulation. This impairment leads to compulsive behavior despite negative consequences. Genetic
predispositions and environmental factors further alter brain plasticity, reinforcing the addictive cycle.

• Dopamine Dysregulation: In severe addiction, the brain's reward system becomes hypersensitive to
drug-related cues, while normal rewards are less pleasurable due to downregulation of dopamine
receptors. This results in tolerance, where more of the substance or behavior is needed for the same
reward, and reduced pleasure from non-addictive stimuli (Volkow et al., 2019)
• Prefrontal Cortex Dysfunction: Addiction leads to structural and functional changes in the
prefrontal cortex, impairing decision- making, self-regulation, and impulse control. These impairments
result in a loss of control over substance use (Goldstein & Volkow, 2011).
 13
Neurobiological Mechanisms
in Addiction
• Stress Systems: Chronic addiction activates the hypothalamic-pituitary-adrenal (HPA) axis and stress
circuits, leading to increased release of stress hormones like corticotropin-releasing factor (CRF). This
heightened stress sensitivity can trigger relapse as individuals seek relief from negative emotional states
(Koob, 2015).

• Allostatic Load: Long-term substance use shifts the brain from homeostasis to allostasis, altering
baseline functioning to accommodate the addiction. This involves persistent changes in neural pathways,
particularly in the amygdala and striatum, which reinforce compulsive use and complicate recovery
(Koob & Volkow, 2010).

• Neuroplasticity Changes: Severe addiction leads to maladaptive neuroplasticity, where changes in

synaptic connections strengthen the compulsion to engage in addictive behaviors, even when they no
longer provide pleasure. Long-term potentiation (LTP) in the glutamatergic system is impaired,
weakening learning and memory processes related to controlling drug-seeking behavior (Kalivas &
O’Brien, 2008).
 14
Substance Use and
Mental Health Outcomes
• Epidemiological data indicate that nearly 50% of individuals with SUDs also have co-
occurring mental disorders, such as mood and anxiety disorders (Grant et al., 2016). Severe mental
illnesses like bipolar disorder and schizophrenia increase the risk of developing SUDs, with early-onset
substance use exacerbating psychiatric symptoms and complicating treatment (Regier et al., 1990;
Buckley et al., 2009).

• The relationship between substance use and mental health outcomes is bidirectional and
cyclical. Chronic substance use often exacerbates psychiatric symptoms, creating a reinforcing cycle of
dependence and worsening mental health. For example, Conway et al. (2006) found that individuals with
mood and anxiety disorders face higher lifetime risks of alcohol and drug dependence, driven by self-
medication that provides temporary relief but ultimately worsens symptoms. Swendsen et al. (2010)
highlighted that early-onset substance use, particularly with cannabis and alcohol, is linked to an
increased risk of developing major depressive disorder (MDD) and generalized anxiety disorder (GAD)
later in life.

• Studies show that severe addiction involves profound changes in brain function. For instance, prolonged
alcohol misuse leads to structural and functional brain abnormalities in the prefrontal cortex, impairing
cognitive control and emotional regulation (Harper, 2009). Stimulant and opioid use cause
dopaminergic dysregulation, resulting in anhedonia and mood disturbances, which contribute
to dependence and emotional instability (Volkow et al., 2017)
 15
Neurobiological Mechanisms
in Addiction
• Koob and Volkow (2016) found that chronic alcohol and opioid use impair reward sensitivity and
increase susceptibility to mood dysregulation and anxiety. Cannabis use has been associated with
an increased risk of psychosis, especially in those with genetic predispositions (Di Forti et
al., 2019).

• The opioid epidemic has further highlighted the co-occurrence of mental health issues with opioid use
disorder (OUD), particularly in economically disadvantaged populations.

• Social determinants, such as socioeconomic status and early-life trauma, also play a
critical role. The Adverse Childhood Experiences Study (ACES) demonstrates that childhood
trauma significantly increases the risk of developing both SUDs and psychiatric disorders later in life,
emphasizing the need for trauma-informed care (Anda et al., 2006).

• Additionally, research should examine how cultural and socioeconomic contexts influence the co-
occurrence of SUDs and mental illnesses globally to refine treatment approaches for diverse
populations.
 17
Comorbidity and Risk
in Psychosis
• Substance-Induced Psychotic Disorder (SIPD): Substance-Induced Psychotic Disorder (ICD-10: F10-
F19; DSM-5: 292.x) manifests primarily through hallucinations and delusions triggered directly by the use
of substances such as cannabis, amphetamines, alcohol, and hallucinogens. Psychotic symptoms
typically present during intoxication or withdrawal, and these symptoms may be indistinguishable from
those of primary psychotic disorders in the acute phase.

⚬ Hallucinations: Individuals using hallucinogens (e.g., LSD, psilocybin) may experience vivid, sensory
distortions, including auditory or visual hallucinations. Stimulants such as cocaine and
methamphetamine are known to induce paranoid delusions and visual hallucinations, particularly with
chronic use or high doses (Smith et al., 2009).

⚬ Delusions: Paranoid delusions are common in SIPD, particularly in chronic users of stimulants and
cannabis. These delusions often take the form of persecution or grandiosity, where the individual may
believe they are being followed, watched, or otherwise targeted by others (Sami et al., 2015). A study
by Di Forti et al. (2014) demonstrated that heavy use of high-potency cannabis significantly raises the
risk of psychotic disorders such as schizophrenia, especially in those with genetic vulnerabilities. This
study also found that psychotic symptoms were more persistent in cannabis users
compared to those with no substance use history.
 18
Comorbidity and Risk
in Psychosis
• Cognitive Impairment: Cognitive deficits, including issues with attention, memory, and executive
functioning, are worsened by substance use in individuals with schizophrenia. Those with comorbid
substance use perform worse on cognitive tests and face challenges with treatment
adherence, impacting their overall prognosis (Verma et al., 2018).

• Trauma, Social Determinants, and Psychosis: Individuals with adverse childhood experiences
(ACEs), including abuse, neglect, or household dysfunction, are at significantly increased risk for both
SUDs and psychotic disorders (Anda et al., 2006).

⚬ Trauma and PTSD: A significant portion of individuals with psychotic disorders and
comorbid substance use have a history of trauma. This is particularly common among
women and individuals from marginalized communities (Read et al., 2005). Trauma often
triggers substance use as a maladaptive coping mechanism, while the neurobiological stress
response may contribute to the development of psychosis, creating a complex and intertwined
relationship.

⚬ Social Determinants: Factors such as poverty, lack of access to healthcare, homelessness,

and unemployment further complicate the management of comorbid SUDs and psychotic
disorders often resulting in a chronic cycle of relapse, hospitalization, and deterioration in
 19
Comorbidity and Risk
in Psychosis
• Neurobiological Mechanisms and Integrated Treatment

⚬ Advances in neuroimaging and genetic research have shed light on the shared
neurobiological mechanisms underlying substance use and psychotic disorders.

⚬ Neurobiological Mechanisms: Both conditions involve disruptions in dopamine regulation

within the mesolimbic reward system. Chronic substance use, particularly with stimulants
and cannabis, leads to over-activation of this pathway, while schizophrenia is characterized by
dopamine dysregulation (Koob & Volkow, 2016).
 20
Comorbidity and Risk
in Mood Disorders
• Substance Use and Major Depressive Disorder (MDD)

⚬ Bidirectional Relationship: Substance abuse can trigger or worsen depressive episodes, while
individuals with MDD may use substances for self-medication.

⚬ Exacerbation of Symptoms: Substance use often heightens symptoms of MDD, including

persistent sadness, hopelessness, and loss of interest. For example, alcohol and sedatives can
intensify depressive feelings and suicidal ideation (Hasin et al., 2015; Sullivan et al., 2007). Alcohol
use has been shown to worsen cognitive impairments and increase suicide risk in MDD patients
(Sullivan et al., 2007).

⚬ Neurobiological Mechanisms: Disruptions in serotonin and norepinephrine systems are

implicated. Alcohol and benzodiazepines can alter neurotransmitter levels, affecting mood
regulation and exacerbating depressive states (Nunes & Levin, 2004).
 21
Comorbidity and Risk
in Mood Disorders
• Substance Use and Bipolar Disorder

⚬ Impact on Mood Episodes: Substance use can trigger manic episodes or exacerbate mood swings.
Stimulants like cocaine can provoke manic symptoms, while depressants like alcohol can
worsen depressive episodes (Swendsen et al., 2010). Substance abuse is associated with more
severe manic episodes and increased risk of relapse (Swendsen et al., 2010).

⚬ Neurobiological Disruptions: Substance use disrupts mood-regulating neurotransmitters.

Stimulants enhance dopamine release, intensifying manic symptoms, whereas depressants inhibit
neurotransmitter activity, worsening depressive states (Perkins et al., 2013). For instance, cocaine
use can exacerbate manic symptoms in bipolar disorder by enhancing dopaminergic activity (Perkins
et al., 2013).

⚬ Trauma and Social Determinants: Individuals with adverse childhood experiences are at a higher
risk for both mood and substance use disorders. Trauma significantly impacts the progression
of these conditions (Anda et al., 2006). Factors such as poverty, lack of social support, and
unemployment exacerbate both mood disorders and substance use. These social determinants
contribute to increased substance use as a coping mechanism and worsen the severity of mood
disorders (Drake et al., 2001).
 22
Comorbidity and Risk in Cognitive
Impairment and Executive Functioning
• Cognitive Impairment in Substance Use Disorders

⚬ Attention and Memory: Chronic substance abuse, including alcohol, cocaine, and
methamphetamine, impairs cognitive functions like attention and memory. Alcohol abuse, in
particular, is associated with significant impairments in working and long-term
memory, affecting learning and retention (Goudriaan et al., 2006).

⚬ Executive Functioning: Executive functions, such as planning, problem-solving, and

impulse control, are notably disrupted by substances. Stimulant abuse, including cocaine
and methamphetamine, impairs these functions by affecting dopamine pathways crucial for
cognitive control and decision-making (Baker et al., 2007).
 23
Comorbidity and Risk in Cognitive
Impairment and Executive Functioning
• Mechanisms of Cognitive Impairment

⚬ Neurotransmitter Disruptions: Substance abuse affects neurotransmitter systems like dopamine,

serotonin, and glutamate, leading to structural brain changes, particularly in the prefrontal
cortex and hippocampus. Chronic use of substances reduces gray matter volume and
impairs neuroplasticity, impacting memory and executive functions (Goldstein & Volkow,
2011; Kalivas, 2009).

⚬ Neuroinflammation and Oxidative Stress: These factors exacerbate cognitive decline by

affecting neural communication and impairing attention and impulse control (Crews &
Vetreno, 2016; Lim et al., 2008). Cognitive impairments often persist even after cessation of
substance use, especially when compounded by mental health conditions like depression or anxiety
(Kornreich et al., 2002; Greenfield et al., 2010).

• Depressive Disorders: Major Depressive Disorder (MDD) combined with substance abuse exacerbates
cognitive deficits, particularly in attention, memory, and executive functions. Co-occurring MDD and
substance abuse lead to greater cognitive impairments compared to each disorder alone
 24
Comorbidity and Risk in Cognitive
Impairment and Executive Functioning
• Anxiety Disorders: Generalized Anxiety Disorder (GAD) or Panic Disorder combined with substance use
can lead to significant impairments in memory and executive functioning, often complicating treatment
(Greenfield et al., 2010).

• Bipolar Disorder: Substance abuse in bipolar disorder exacerbates cognitive deficits related to impulse
control, planning, and emotional regulation, complicating treatment and management (Cardoso de Almeida
& Laranjeira, 2005).

• Attention Deficit Hyperactivity Disorder (ADHD): Substance use, especially stimulants, exacerbates
executive function deficits in individuals with ADHD, leading to difficulties in planning, organization, and
decision-making (Baker et al., 2007).

• Schizophrenia: Substance abuse, particularly stimulants and cannabis, worsens cognitive deficits in
schizophrenia, affecting working memory and executive functions. This comorbidity results in poorer
treatment outcomes and greater functional impairment (Green et al., 2008).
 25
Comorbidity and Risk in Cognitive
Impairment and Executive Functioning
Geriatric Conditions
• Alcohol-related Dementia (ARD): Chronic alcohol abuse can cause ARD, marked by memory and
executive functioning deficits. Neurotoxic effects of alcohol accelerate cognitive aging by affecting brain
areas such as the prefrontal cortex and hippocampus (Sachdev et al., 2001).

• Wernicke-Korsakoff Syndrome: Caused by chronic alcohol abuse and thiamine deficiency, this
syndrome is characterized by memory loss, confusion, and motor dysfunction, common in older
adults with prolonged alcohol use (Victor et al., 1989).

• Alzheimer’s Disease (AD): Substance abuse, particularly alcohol and benzodiazepines, may increase
the risk or accelerate the progression of AD. Heavy drinking exacerbates cognitive decline and
worsens neuroinflammation, contributing to AD pathogenesis (Pope et al., 2015).

• Vascular Dementia: Substance abuse can worsen cardiovascular issues, leading to vascular dementia,
characterized by impairments in executive functioning, memory, and processing speed (Kalaria,
2010).

• Delirium: Older adults who misuse substances like alcohol or opioids are at higher risk for delirium, an
acute state of confusion with disorientation, memory loss, and hallucinations (Inouye, 2006).
 26
Comorbidity and Risk in Cognitive
Impairment and Executive Functioning
Geriatric Conditions

• Mood Disorders and Late-life Depression: Substance abuse in older adults can trigger or worsen
late-life depression, leading to mood instability and cognitive impairment. This can result in
pseudo-dementia, where depressive symptoms mimic dementia (Blazer, 2003).

• Chronic Pain and Substance Abuse: Misuse of opioids for chronic pain management can
lead to cognitive decline and higher risk of falls and fractures, exacerbating cognitive
impairments and mood disturbances (Veal, 2011).

• Polypharmacy and Drug Interactions: Older adults on multiple medications may

experience increased cognitive impairment due to interactions with substances like
alcohol, leading to delirium, falls, and hospitalization (Lechevallier-Michel et al., 2005).

• Anxiety Disorders and Benzodiazepine Misuse: Misuse of benzodiazepines in older adults with
anxiety disorders leads to cognitive impairments, including memory problems and slowed reaction
time, and is associated with an increased risk of dementia (Billioti de Gage et al., 2014).
 27
Comorbidity and Risk in
Personality Disorder
• Borderline Personality Disorder (BPD): BPD is characterized by unstable moods, self-image,
and relationships, often accompanied by impulsivity. Substance abuse, used as self-medication, can
exacerbate these symptoms, increasing emotional instability and impulsivity. Substances like
alcohol and cocaine can worsen mood swings and emotional dysregulation (Linehan,
1993). Neurobiological changes due to substance abuse affect areas involved in emotion regulation,
such as the prefrontal cortex and amygdala, intensifying BPD symptoms (Miller et al., 2008).

• Antisocial Personality Disorder (ASPD): ASPD involves a pattern of disregard for others' rights
and norms. Substance abuse in ASPD individuals often escalates aggressive and antisocial
behaviors, increasing criminal activity and interpersonal conflicts. This abuse impairs impulse
control and amplifies violent outbursts (Black et al., 2010). The interaction between substance
abuse and ASPD disrupts brain regions responsible for impulse control and aggression,
like the orbitofrontal cortex and amygdala (Kraus et al., 2009).
 28
Comorbidity and Risk in
Personality Disorder
• Narcissistic Personality Disorder (NPD): NPD is marked by grandiosity, need for admiration, and lack
of empathy. Substance abuse in NPD individuals may reinforce their grandiose self-image or manage
insecurities, exacerbating traits such as grandiosity and entitlement. This abuse can lead to increased
risk-taking behaviors and interpersonal conflicts (Miller & Campbell, 2008). Substance abuse
affects brain regions involved in self-esteem and reward processing, such as the ventral
striatum and prefrontal cortex, intensifying narcissistic behaviors (Miller et al., 2007)
• Avoidant Personality Disorder (AVPD): AVPD is characterized by extreme shyness, feelings of
inadequacy, and hypersensitivity to negative evaluation. Substance abuse, particularly alcohol, is
often used to manage social anxiety. While it may temporarily alleviate anxiety, it can worsen
long-term social functioning and self-esteem (Ribisl et al., 1997). This abuse affects brain
regions involved in social cognition and anxiety regulation, like the amygdala and prefrontal
cortex, increasing social avoidance (Schmidt et al., 2011)
• Obsessive-Compulsive Personality Disorder (OCPD): OCPD involves a preoccupation with
orderliness, perfectionism, and control. Substance abuse disrupts rigid routines and exacerbates
perfectionistic tendencies, leading to increased anxiety related to perceived loss of control
(Frost et al., 2003). The abuse affects brain regions involved in cognitive control and anxiety regulation,
such as the anterior cingulate cortex and orbitofrontal cortex, increasing distress and rigidity (Stein et al.,
2007).
 29
Substance Abuse and its Comorbidities with
Neurodegenerative Diseases
Substance abuse has been associated with an increased risk of developing neurodegenerative diseases.
These conditions are characterized by progressive degeneration of the nervous system, leading to
cognitive and motor impairments

• Alzheimer’s Disease (AD): Substance abuse, particularly alcohol, is known to impact the risk and
progression of AD. Chronic alcohol consumption is associated with an increased risk of developing
Alzheimer's Disease. Alcohol-induced neurotoxicity, including the formation of neurofibrillary
tangles and amyloid plaques, contributes to cognitive decline and accelerates AD
progression (Pfefferbaum et al., 1998). Pfefferbaum et al. (1998) found that chronic alcohol abuse
led to significant neurotoxic effects, including neuronal loss and cognitive impairment, which may
contribute to the development and acceleration of Alzheimer's Disease.

• Parkinson’s Disease (PD): Parkinson’s Disease is characterized by the degeneration of

dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremor,
rigidity, and bradykinesia. Substance abuse, especially with drugs like methamphetamine,
can influence Parkinson’s Disease. Methamphetamine abuse has been linked to increased
risk and accelerated progression of Parkinson’s Disease. Methamphetamine induces
neurotoxicity that damages dopaminergic neurons, exacerbating motor symptoms and accelerating
disease progression (Kish et al., 2008).
 30
Substance Abuse and its Comorbidities with
Neurodegenerative Diseases

• Huntington’s Disease (HD): Huntington’s Disease is a genetic neurodegenerative disorder

characterized by chorea, psychiatric symptoms, and cognitive decline. Substance abuse can
complicate the clinical management and progression of HD. Substance abuse, including
alcohol and cocaine, can exacerbate the motor and cognitive symptoms of Huntington’s
Disease. The use of substances can interfere with disease management and increase the severity of
symptoms (Duff et al., 2007).

• Amyotrophic Lateral Sclerosis (ALS): Amyotrophic Lateral Sclerosis is a progressive

neurodegenerative disease affecting motor neurons, leading to muscle weakness and atrophy.
Substance abuse can impact ALS progression and symptom management. Substance
abuse, particularly with drugs like alcohol and nicotine, has been linked to increased risk
and accelerated progression of ALS. These substances may contribute to neuronal
damage and exacerbate motor symptoms (Miller et al., 2009). Miller et al. (2009) found that
alcohol and nicotine use in ALS patients contributed to increased disease progression and worsening
of motor symptoms, highlighting the impact of substance abuse on ALS.
 31
Comorbidity and Risk in
Impulsive Behaviors in Adolescents
• General Impulsivity and Substance Abuse: Adolescents are especially vulnerable to substance
abuse due to the immature development of brain regions responsible for impulse control,
such as the prefrontal cortex. This immaturity leads to heightened impulsivity and
increased risk of substance use (Steinberg, 2008). Impulsivity in substance use disorders is
marked by actions taken without forethought and a preference for immediate rewards, which
increases risky behaviors and substance experimentation. Substance abuse exacerbates
impulsivity, leading to erratic and aggressive behavior, frequent peer conflicts, and social
isolation (Grant et al., 2006; Swann, 2006). The combination of substance abuse and impulsivity
often results in withdrawal from social activities and support networks, exacerbating
feelings of loneliness and depression (Koob & Volkow, 2016; McElroy et al., 2001).

• Attention-Deficit/Hyperactivity Disorder (ADHD): Adolescents with ADHD are at a higher risk

for substance abuse due to their inherent impulsivity and hyperactivity. Substance use can
exacerbate ADHD symptoms, such as inattention and impulsivity, complicating treatment and daily
functioning (Biederman et al., 2008). Substance abuse disrupts neurotransmitter systems, particularly
dopamine and norepinephrine, further amplifying impulsivity and impairing executive functions
(Kollins, 2008).
 32
Comorbidity and Risk in
Impulsive Behaviors in Adolescents
• Conduct Disorder (CD): Conduct Disorder, characterized by severe antisocial behaviors, often co-
occurs with substance abuse. Substance use can escalate impulsive and aggressive behaviors
in youths with CD, leading to more severe conduct issues and a higher likelihood of
criminal activities (Frick & Viding, 2009). This escalation results from substance-induced disruption
of brain regions involved in impulse control, complicating management and treatment (Nederhof et
al., 2011).

• Bipolar Disorder (BD): Substance abuse complicates Bipolar Disorder in adolescents. During manic
episodes, substance use can exacerbate impulsivity and risk-taking behaviors, while during
depressive episodes, it can worsen depressive symptoms and impulsivity (McElroy et al., 2001).
Substance abuse disrupts mood-regulating neurotransmitters, such as serotonin and dopamine,
leading to increased impulsivity and mood instability (Swann, 2006).

• Impulse-Control Disorders (ICDs): Impulse-Control Disorders, including intermittent

explosive disorder and compulsive gambling, are closely linked with substance abuse.
Substance use can increase impulsive behaviors associated with ICDs, further impairing impulse
control and exacerbating symptoms such as explosive anger or compulsive behaviors (Grant et al.,
2006; Koob & Volkow, 2016).
 33
Comorbidity and Risk in
Impulsive Behaviors in Adolescents
• Post-Traumatic Stress Disorder (PTSD): Adolescents with PTSD may use substances to self-
medicate symptoms such as intrusive memories, hyperarousal, and avoidance behaviors.
Substance abuse can exacerbate the core symptoms of PTSD, including impulsivity, aggression, and
emotional dysregulation, leading to a cycle of increased substance use and worsening PTSD
symptoms (McFarlane, 2001; Cohen et al., 2006).

• Eating Disorders: Substance abuse often co-occurs with eating disorders such as bulimia nervosa or
anorexia nervosa in adolescents. The impulsivity and compulsivity associated with substance
use can mirror or exacerbate disordered eating behaviors, leading to a complex interplay
of symptoms and complicating treatment outcomes (Hudson et al., 2007; Wilfley et al.,
2007).

• Autism Spectrum Disorder (ASD): Adolescents with Autism Spectrum Disorder may be at risk for
substance abuse due to difficulties with social skills and impulse control. Substance use may serve
as a maladaptive coping mechanism for managing anxiety or sensory processing issues,
potentially worsening behavioral and cognitive challenges (Hoffman et al., 2018;
McPartland et al., 2012).
 34
Comorbidity and Risk in
Impulsive Behaviors in Adolescents
• Schizotypal Personality Disorder : Adolescents with schizotypal personality disorder,
characterized by odd beliefs and eccentric behavior, may be at higher risk for substance abuse.
Substance use can exacerbate symptoms like paranoia and odd behaviors, further
impairing social functioning and increasing the risk of psychosis (Kirkpatrick et al., 2006).

• Obsessive-Compulsive Disorder (OCD) : Substance abuse in adolescents with OCD can lead to a
worsening of obsessive and compulsive symptoms. The impulsive behavior associated with
substance use may interfere with the individual's ability to engage in therapeutic
interventions for OCD, complicating treatment (Pittenger et al., 2011; Gonen et al., 2014).
 36
Assessment Plan for Substance Use
and Comorbid Mental Health Conditions
• Initial Clinical Interview

⚬ Building Rapport: Establish trust with the client, addressing stigma and denial related to
substance use and mental illness (Tolin, 2010).
⚬ Gathering Comprehensive History: Include medical, psychiatric, and substance use history,
as well as social, occupational, and family history. Explore the onset, duration, severity of
symptoms, and previous treatment attempts (McLellan et al., 2000).
⚬ Symptom Inquiry: Identify symptoms of both substance use disorders (SUDs) and mental
health conditions. Differentiate between substance-induced and primary psychiatric
symptoms (Kranzler & Blume, 2000).

Tools:

⚬ Structured Clinical Interview for DSM-5 (SCID-5): Semi-structured guide for diagnosing DSM-
5 disorders, helpful in distinguishing between primary psychiatric and substance-induced
conditions (First et al., 2015).
⚬ Mini International Neuropsychiatric Interview (MINI): Short, structured diagnostic interview
for mental health disorders and SUDs (Sheehan et al., 1998).
 37
Assessment Plan for Substance Use
and Comorbid Mental Health Conditions

• Substance use assessment

⚬ Substance Use History (Triggers): Assess types, frequency, quantity, duration, context
of use, periods of abstinence, and triggers for relapse (Dennis & Scott, 2007).
⚬ Patterns and Consequences (Spread): Evaluate the impact on physical health, mental health,
relationships, legal status, and occupational functioning (Jones & Day, 2008).
⚬ Motivation for Change: Assess readiness to change substance use behaviors (Prochaska &
DiClemente, 1983).

Tools:

⚬ Alcohol Use Disorders Identification Test (AUDIT): Screen for alcohol consumption and
related problems (Saunders et al., 1993).
⚬ Drug Abuse Screening Test (DAST): Screen for drug use problems and severity (Skinner, 1982).
 38
Assessment Plan for Substance Use
and Comorbid Mental Health Conditions

• Mental Health Assessment

⚬ Psychiatric Symptom Assessment: Assess mood, anxiety, psychotic, and cognitive symptoms.
Determine if symptoms predate or emerged after substance use (Regier et al., 1990).
⚬ Risk Assessment: Evaluate the risk of suicide, self-harm, and harm to others (Brown & Beck,
2002).

Tools:

⚬ Beck Depression Inventory (BDI): Assess severity of depressive symptoms (Beck et al., 1961).
⚬ Beck Anxiety Inventory (BAI): Assess severity of anxiety symptoms (Beck et al., 1988).
⚬ Positive and Negative Syndrome Scale (PANSS): Assess severity of symptoms in psychotic
disorders (Kay et al., 1987).
 39
Assessment Plan for Substance Use
and Comorbid Mental Health Conditions
• Cognitive and Neuropsychological Assessment: Evaluate cognitive impairments, especially in
the context of comorbid conditions:

⚬ Cognitive Screening: Assess memory, attention, executive function, and processing speed
(Kalapatapu & Schmitz, 2007).

• Neuropsychological Testing: For significant cognitive impairments, conduct a full evaluation to

identify specific deficits.

Tools:

⚬ Montreal Cognitive Assessment (MoCA): Screen for mild cognitive impairment (Nasreddine et
al., 2005). It is mainly used for patients above 55 years of age.
⚬ Wechsler Adult Intelligence Scale (WAIS-IV): Comprehensive assessment of cognitive
functioning (Wechsler, 2008).
 40
Assessment Plan for Substance Use
and Comorbid Mental Health Conditions

• Assessment of Personality Disorders

⚬ Personality Disorder Screening: Assess for features of personality disorders, particularly borderline,
antisocial, and narcissistic personality disorders.

Tools:

⚬ Millon Clinical Multiaxial Inventory (MCMI-IV): Self-report questionnaire for personality

disorders and clinical syndromes (Millon, 2015).
⚬ Personality Assessment Inventory (PAI): Self-report measure for personality traits and
psychopathology (Morey, 2007).
 41
Assessment Plan for Substance Use
and Comorbid Mental Health Conditions

• Behavioral and Environmental Assessment: Understand the client's behavior and

environment

⚬ Behavioral Assessment: Identify patterns related to substance use, triggers, and coping
mechanisms.
⚬ Environmental Factors: Assess living situation, social supports, and environmental
triggers for substance use.

• Physical Health Assessment: Substance use impacts physical health

⚬ Medical Evaluation: Assess for health problems associated with substance use, such as
liver disease, cardiovascular issues, and infectious diseases.
⚬ Laboratory Testing: Conduct tests (e.g., liver function tests, toxicology screens) to obtain
objective data on substance use impacts.
 42
Assessment Plan for Substance Use
and Comorbid Mental Health Conditions
• Integrative Case Formulation: Integrate assessment findings into a comprehensive case
formulation:

⚬ Biopsychosocial Model: Integrate biological, psychological, and social factors.

⚬ Diagnosis: Provide differential diagnosis considering substance-induced and primary psychiatric
disorders.
⚬ Treatment Planning: Develop an individualized treatment plan addressing both substance use
and comorbid conditions, including pharmacological interventions, psychotherapy, and social
support services.

• Continuous Monitoring and Reassessment: Ongoing monitoring is essential for effective

treatment:

⚬ Regular Follow-Up: Schedule follow-up appointments to monitor progress and adjust treatment
as needed.
⚬ Outcome Measures: Use standardized measures to assess treatment effectiveness and guide
clinical decisions.
 43
Role of the Mental Status Examination (MSE) in
Assessing Substance Use and Mental Health Comorbidity

In the context of comorbid substance use and psychiatric disorders MSE will help clinicians
differentiate between symptoms attributable to substance use and those arising from
primary psychiatric conditions.

• Appearance and Behavior

⚬ Unkempt appearance, tremors, or hyperactivity: Common in substance intoxication or

withdrawal (e.g., alcohol or stimulants).
⚬ Agitation vs. lethargy: Agitation may indicate stimulant use, while lethargy can suggest
depressant use like alcohol or opioids.
⚬ Delirium from intoxication: Acute delirium can mimic psychiatric disorders, especially in cases
of heavy alcohol or polysubstance use (NMIH, 2022).
⚬ Grooming decline: Seen not only in substance abuse but also in alcohol-induced neurocognitive
disorders, indicating progressive cognitive decline (NMIH, 2020).
 44
Role of the Mental Status Examination (MSE) in
Assessing Substance Use and Mental Health Comorbidity
• Speech

⚬ Slurred speech: Suggests intoxication from alcohol or sedatives, while rapid, pressured speech
may indicate stimulant intoxication or mania.
⚬ Dysarthria (expeirencing sudden changes in your ability to speak): Seen in alcohol and
benzodiazepine use; differentiating this from neurological speech disorders is crucial (NMIH,
2021).

• Mood and Affect

⚬ Elevated mood: Could indicate mania or stimulant intoxication (e.g., cocaine, amphetamines).
⚬ Depressed mood: Often observed in alcohol use or substance withdrawal.
⚬ Labile mood: Common in individuals with comorbid borderline personality disorder and
substance use disorders.
⚬ Stimulant-induced mania: Stimulants may cause acute manic symptoms which
generally subside after withdrawal, unlike the sustained mania in bipolar disorder
(NMIH, 2023).
⚬ Blunted affect in cannabis users: Chronic users often present with blunted affect,
 45
Role of the Mental Status Examination (MSE) in
Assessing Substance Use and Mental Health Comorbidity

• Thought Process

⚬ Disorganized thinking or flight of ideas: Often present in psychosis or mania, and

exacerbated by hallucinogens or stimulants.
⚬ Stimulant-induced paranoia: This type of paranoia is typically transient and linked to
active drug use, unlike persistent paranoia seen in psychotic disorders (NMIH, 2019).

• Thought Content

⚬ Suicidal ideation, paranoia, or delusions: These may indicate schizophrenia, bipolar

disorder, or substance-induced psychosis.
⚬ Differentiating paranoia: It's important to assess whether paranoid delusions are
substance-induced (e.g., from stimulants like methamphetamine) or a feature of a primary
psychotic disorder (NMIH, 2021).
 46
Role of the Mental Status Examination (MSE) in
Assessing Substance Use and Mental Health Comorbidity

• Perceptual Disturbances

⚬ Hallucinations: Common in both substance use and psychiatric disorders (e.g., auditory
hallucinations in schizophrenia vs. tactile hallucinations in methamphetamine use).
⚬ Formication (sensation of insects under the skin): A common symptom of stimulant use
withdrawal that must be distinguished from hallucinations seen in psychotic disorders
(NMIH, 2021).

• Cognition

⚬ Memory impairments, poor concentration, and executive dysfunction: Seen in alcohol-

induced neurocognitive disorders, delirium, or long-term substance use.
⚬ Alcohol-related cognitive deficits: Chronic alcohol use can lead to severe deficits in executive
functioning and memory, particularly in conditions like Wernicke-Korsakoff syndrome (NMIH, 2023).
⚬ Substance-induced delirium: Patients often exhibit fluctuating cognition, making it crucial
to differentiate from dementia or other neurocognitive disorders (NMIH, 2021).
 47
Role of the Mental Status Examination (MSE) in
Assessing Substance Use and Mental Health Comorbidity

• Insight and Judgment

⚬ Poor insight into substance-related consequences: Seen in both substance use disorders and
comorbid conditions like bipolar disorder and personality disorders.

⚬ Dual diagnosis: Individuals with both substance use disorders and personality disorders often
struggle with poor judgment, which complicates treatment. Integrated care approaches are
emphasized to manage such complexities (NMIH, 2022).
 48
Role of the Mental Status Examination (MSE) in
Assessing Substance Use and Mental Health Comorbidity

• Therapeutic Disruptions

⚬ Erratic Attendance and Missed Sessions: Substance use often results in physical and
emotional instability, causing clients to miss therapy sessions due to hangovers, legal
issues, or health complications (McLellan et al., 2000). Frequent cancellations disrupt
therapeutic consistency and force clinicians to frequently adjust treatment plans,
focusing on crisis intervention instead of long-term goals (Dennis & Scott, 2007).

⚬ Crisis Intervention: Crisis intervention becomes essential during periods of instability,

shifting focus from long-term goals to immediate safety concerns. Models like Safety
Planning Intervention (SPI) manage acute risks such as suicidal ideation and substance
overdose (Stanley et al., 2018).

⚬ Contingency Management (CM): CM is a highly effective behavioral strategy that

provides tangible incentives, such as vouchers or monetary rewards, for maintaining
sobriety and achieving treatment goals. It is especially useful for maintaining engagement
during low motivation periods and early sobriety (Higgins et al., 1991; Peirce et al., 2006).
 49
Impact on the Therapeutic Process
• Emotional Dysregulation

⚬ Impact on Therapy: Emotional dysregulation, common in substance use disorders and co-
occurring mental health conditions (e.g., borderline personality disorder, PTSD), leads to mood
swings and impulsive actions, disrupting therapy progress (Linehan, 1993; Gunderson, 2011).

⚬ Dialectical Behavior Therapy (DBT): DBT, originally designed for borderline personality
disorder, is effective in managing emotional dysregulation through emotional regulation and
mindfulness, which helps clients manage impulses and tolerate distress (Linehan, 1993;
Harned et al., 2012).

⚬ Neurobiological Underpinnings: Emotional dysregulation often involves dysregulated

neurotransmitter systems, exacerbated by substance use, creating a feedback loop that
heightens emotional reactivity. Addressing both psychological and biological factors, including
psychoeducation on neurobiological impacts, is crucial (Koob & Volkow, 2010; Volkow et al.,
2014).
 50
Impact on the Therapeutic Process
• Relapse and Treatment Resistance

⚬ Cycle of Relapse: Relapse is common, especially early in treatment and during stress. Viewing
relapse as part of the recovery process helps in recalibrating treatment plans and
addressing triggers (Marlatt & Donovan, 2005).

⚬ Relapse Prevention Strategies: Techniques such as mindfulness-based relapse prevention

(MBRP) help clients recognize early warning signs of relapse and manage cravings
without acting on them

⚬ Treatment Resistance: Clients with significant trauma histories or long-term substance use may
resist therapy due to dependence on substances for emotional regulation. Trauma-
informed care focuses on creating a safe and collaborative therapeutic environment (Harris & Fallot,
2001).

⚬ Integrated Treatment: Integrated treatment, addressing both substance use and mental health
conditions concurrently, is more effective than sequential treatment. The Integrated Dual
Diagnosis Treatment (IDDT) model emphasizes concurrent therapy and skill-building
(Mueser et al., 2003).

⚬ Motivational Interviewing (MI): MI helps address ambivalence toward change, improving the
therapeutic alliance and encouraging gradual recovery steps (Miller & Rollnick, 2013).
 51
Impact on the Therapeutic Process
• Final Stages and Aftercare

⚬ Sustaining Recovery: Maintaining sobriety and managing mental health long-term involves
robust aftercare plans, including engagement in support groups like Alcoholics
Anonymous (AA) or Narcotics Anonymous (NA) to prevent isolation and relapse
(Vaillant, 2003).

⚬ Building Long-Term Sobriety Skills: Cognitive Behavioral Therapy (CBT) helps clients
challenge distorted thoughts that may lead to relapse and reinforces positive coping mechanisms
(Beck, 1979).

⚬ Peer Support Integration: Engagement in peer-led support groups offers additional

social support and accountability. Combining these groups with individual therapy
creates a comprehensive support system (Kaskutas, 2009).

⚬ Social Reintegration: Focus on social reintegration, including vocational counseling and

occupational therapy, to help clients re-enter the workforce and improve social
interactions after substance use and mental illness disruptions (Drake et al., 2003).
 52
Clinician Considerations for treating
Substance Abuse and Comorbid Mental Illness
• Comprehensive Evaluation: A thorough evaluation is foundational for effective treatment. It
involves understanding the full scope of the client's substance use, mental health conditions,
and life context (Miller & Rollnick, 2013). Distinguishing between primary mental health
disorders and substance-induced symptoms is crucial to avoid misdiagnosis and to tailor treatment
appropriately (Hyman & Malenka, 2001). This initial assessment sets the stage for all
subsequent treatment planning and interventions.

• Client-Centered Care: Building a strong therapeutic alliance is essential for fostering trust and
openness, particularly with clients who may be reluctant to share sensitive information due
to stigma or fear or experience shame (Horvath & Bedi, 2002). Incorporating cultural sensitivity
into care is also important, as clients’ cultural backgrounds can influence their views on
substance use and mental health (Sue & Sue, 2012). Assessing the client’s readiness to change
and employing motivational interviewing techniques can further enhance engagement and motivation
(Miller & Rollnick, 2013). This client-centered approach ensures that treatment is not only effective but
also respectful and responsive to individual needs
 53
Clinician Considerations for treating
Substance Abuse and Comorbid Mental Illness
• Risk Assessment and Management: Effective risk management begins with thorough assessments
for suicidal ideation, self-harm, or potential harm to others (Brown & Beck, 2002). Developing a
comprehensive safety plan and considering crisis intervention strategies are crucial for managing these
risks (Powers et al., 2011). Clinicians must be prepared to make timely referrals to crisis services or
emergency care as needed. This proactive stance on risk management ensures that clients receive
immediate support in critical situations, thereby enhancing overall safety.

• Integrated Treatment Planning: Addressing substance use and mental health conditions
simultaneously through integrated treatment is more effective than treating them separately (Drake et
al., 2001).This integrated approach facilitates a more holistic treatment strategy, addressing all aspects
of the client’s condition.

• Social and Environmental Factors: Assessing and enhancing the client's social support
network, including family, friends, and community resources, is crucial for improving treatment
outcomes (McKay, 2009). Additionally, evaluating the client’s living environment is important, as it can
significantly impact their treatment and recovery. Addressing social and environmental factors helps
create a supportive context for the client’s ongoing/future recovery.
 54
Clinician Considerations for treating
Substance Abuse and Comorbid Mental Illness
• Coordination of Care: A collaborative approach involving addiction specialists,
psychiatrists, and primary care physicians is crucial for comprehensive treatment (Wagner
et al., 2007). This multidisciplinary collaboration ensures that clients receive well-rounded
support and reduces the risk of fragmented care.

• Treatment Adherence and Ongoing Monitoring: Clinicians must address potential barriers to
treatment adherence, such as ongoing substance use or lack of insight into mental health
issues (Carroll et al., 2006). Regular follow-ups and assessments are necessary to adjust treatment
plans and address emerging issues or relapses (Sisson & Azrin, 2001). Continuous monitoring helps
maintain treatment efficacy and adapt strategies as the client’s needs evolve.

• Medication Management: Careful management of medications is required to address

potential interactions with substances and mitigate side effects (Rohde et al., 2006). Utilizing
evidence-based therapeutic interventions, such as Cognitive Behavioral Therapy (CBT) for substance
use and Dialectical Behavior Therapy (DBT) for mood disorders, is essential for effective treatment
(Hofmann et al., 2012; Linehan, 1993). This careful approach to medication management ensures that
treatment remains both safe and effective.
 55

Implication for Treatment

• Focus on Client Engagement and Cultural Sensitivity: The emphasis on client-centered care
and cultural sensitivity highlights the need for clinicians to be skilled in building therapeutic alliances
and understanding diverse cultural perspectives (Horvath & Bedi, 2002; Sue & Sue, 2012).
Ongoing training and awareness are required to effectively engage clients and tailor
interventions to their unique cultural contexts.

• Understanding the Cultural Context: The clinician should recognize that in South Asian cultures,
the concept of family honor (izzat) is central to an individual’s identity and actions. The
client’s behavior, including addiction, is often seen as a reflection on the family as a whole. This
means that clients may experience intense pressure to avoid any behavior that could bring shame to
their family, leading to avoidance or denial of their substance use.

• In American culture, particularly in families that emphasize independence and self-sufficiency,

addiction is often framed as a personal failure. The client may feel pressure to overcome his
addiction on his own without seeking outside help, as doing so could be seen as a sign of weakness.
This belief can discourage individuals from engaging in therapy and reaching out for support.
 56

Future Scope and Directions

• Integrated Treatment Models: Expanding integrated treatment programs that address both
conditions within a unified framework is essential for providing cohesive and holistic care (Drake et
al., 2001). Enhanced collaboration among mental health professionals, addiction
specialists, and primary care providers can facilitate more effective management of
complex cases (Ehrlich et al., 2018).

• Personalized Approaches: Advances in personalized medicine and precision psychiatry

enable interventions to be tailored based on individual genetic, biological, and
psychosocial factors (Insel, 2013; Miller & Rollnick, 2013). These approaches can improve the
effectiveness of treatment by targeting the specific interactions between substance use and mental
health conditions.

• Technological Innovations (as an additional support): The rise of mobile health

applications, telehealth platforms, and remote monitoring tools offers new opportunities
for enhancing access to care and monitoring progress (Zhou et al., 2015; Cucciare et al.,
2013). These technologies can bridge gaps in access, particularly for individuals in underserved or
remote areas.
 57

Future Scope and Directions

• Prevention and Early Intervention: Developing and implementing preventive programs aimed
at at-risk populations is critical for reducing the onset of substance use and mental
health disorders (Jensen et al., 2014). Early detection and intervention strategies can mitigate
the long-term impact of these conditions (Harris et al., 2011).

• Evidence-Based Practices: Supporting research that explores the mechanisms linking substance
use and mental illness is crucial for identifying effective treatment modalities (Kessler et al.,
2003). The development and dissemination of evidence-based guidelines will ensure that clinicians
have access to the latest and most effective treatment approaches (SAMHSA, 2017).

• Policy and Advocacy: Advocating for increased funding and resources for integrated
treatment services is vital for expanding access to comprehensive care (National Institute
on Drug Abuse, 2018). Policy changes aimed at reducing barriers and supporting integrated
systems of care will enhance the ability of individuals with co-occurring disorders to receive the help
they need (Wagner et al., 2007).
 58

End note

• The relationship between mental illness and substance use is deeply complex, with the two often
so fused that distinguishing one from the other becomes a clinical challenge. Symptoms of
mental illness may be masked by substance use, and conversely, substance use can
exacerbate or mimic psychiatric symptoms, making accurate diagnosis and intervention
particularly difficult.

• This intricate overlap requires careful defusion using multidimensional assessments like DSM-5 and
ICD-10 frameworks, which allow clinicians to disentangle the symptoms. Integrated care models are
critical, offering a patient-centered approach that addresses both conditions simultaneously, ensuring
treatment is tailored to individual risk factors, comorbidities, and history.

• Patient education plays a vital role in fostering recovery, as understanding the interaction
between mental illness and substance use empowers individuals to actively participate in
their treatment and recognize how each disorder influences the other. Advances in
neuroscience and precision medicine offer hope for developing more targeted therapies,
but patient education and integrated interventions remain central to long-term success.
 59
Bibliography
• Addington, J., & Addington, D. (2007). Substance use and the course of early schizophrenia. Journal of Psychiatry & Neuroscience, 32(3), 195-
200.
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric
Publishing.
• Anda, R. F., Felitti, V. J., Bremner, J. D., Walker, J. D., Whitfield, C. L., Perry, B. D., ... & Giles, W. H. (2006). The enduring effects of abuse and
related adverse experiences in childhood. European Archives of Psychiatry and Clinical Neuroscience, 256(3), 174-186.
[Link]
• Baker, L. E., Tinklenberg, J. R., & Jorgensen, B. H. (2007). Cognitive deficits in substance abuse. Psychiatric Clinics of North America, 30(2),
335-355. [Link]
• Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety: Psychometric properties. Journal of
Consulting and Clinical Psychology, 56(6), 893-897. [Link]
• Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry,
4(6), 561-571. [Link]
• Beck, J. S. (1979). Cognitive therapy of depression. Guilford Press.
• Becker, J. B., & Koob, G. F. (2016). Sex differences in animal models: Focus on addiction. Pharmacological Reviews, 68(2), 242-263.
[Link]
• Biederman, J., Faraone, S. V., & Monuteaux, M. C. (2008). Attention-deficit/hyperactivity disorder and substance use disorders: A review.
Journal of the American Academy of Child and Adolescent Psychiatry, 47(3), 226-233. [Link]
• Biederman, J., Wilens, T. E., & Mick, E. (2008). Attention-deficit/hyperactivity disorder and substance use disorders: The nature of the
association. Journal of the American Academy of Child & Adolescent Psychiatry, 47(3), 262-271.
[Link]
• Billioti de Gage, S., Bégaud, B., Bazin, F., & Verdoux, H. (2014). Benzodiazepine use and risk of Alzheimer’s disease: Case-control study. The
British Journal of Psychiatry, 204(3), 152-158. [Link]
• Black, D. W., Gabel, J., & Schlosser, S. (2010). Substance abuse in patients with Antisocial Personality Disorder. Journal of Clinical Psychiatry,
71(2), 150-155. [Link]
• Blanco, C., Iza, M., & Wang, S. (2013). The epidemiology of substance use disorders and comorbid mental disorders. Current Opinion in
Psychiatry, 26(3), 212-216. [Link]
 60
Bibliography
• Cardoso de Almeida, J., & Laranjeira, R. (2005). Cognitive function in patients with bipolar disorder. Bipolar Disorders, 7(1), 49-55.
[Link]
• Carroll, K. M., Ball, S. A., Martino, S., Nich, C., Frankforter, T. L., & McCance-Katz, E. F. (2006). Computer-assisted training for therapists in
motivational interviewing and cognitive-behavioral therapy. Drug and Alcohol Dependence, 81(1), 1-11.
[Link]
• Cohen, J. A., & Mannarino, A. P. (2006). Substance use and post-traumatic stress disorder in adolescents: A review. Journal of Clinical Psychiatry,
67(11), 2116-2121. [Link]
• Conway, K. P., Swendsen, J. D., Degenhardt, L., & Conway, K. P. (2006). Association between lifetime substance use disorders and psychiatric
disorders in adolescents and adults. American Journal of Psychiatry, 163(5), 798-805.
• Corrigan, P. W. (2004). How stigma interferes with mental health care. American Psychologist, 59(7), 614-625.
[Link]
• Corrigan, P. W., Watson, A. C., & Barr, L. (2006). The self-stigma of mental illness: Implications for self-esteem and self-efficacy. Journal of Social
and Clinical Psychology, 25(8), 875-884. [Link]
• Crews, F. T., & Vetreno, R. P. (2016). Neurogenesis, inflammation, and alcoholism. Brain, Behavior, and Immunity, 57, 1-5.
[Link]
• Cucciare, M. A., Weingardt, K. R., & O’Brien, K. K. (2013). The role of technology in behavioral health interventions: Current research and future
directions. Behavioral Sciences, 3(3), 253-274. [Link]
• Dennis, M. L., & Scott, C. K. (2007). Creating a framework for evaluating treatment outcomes. Journal of Substance Abuse Treatment, 32(3), 233-
243. [Link]
• Di Forti, M., Marconi, A., & Lewis, C. M. (2014). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry, 204(6), 370-375.
• Di Forti, M., Marconi, A., Carra, G., Ottoni, L., Frascarelli, M., & Trotta, A. (2019). The contribution of cannabis use to the risk of psychosis in people
with genetic predisposition. Psychological Medicine, 49(8), 1305-1312. [Link]
• Drake, R. E., McHugo, G. J., & Becker, D. R. (2003). A review of the evidence for the effectiveness of supported employment. Journal of Mental
Health, 12(5), 511-523. [Link]
• Drake, R. E., Mueser, K. T., & Brunette, M. F. (2001). Dual diagnosis: A review. Journal of Dual Diagnosis, 1(1), 15-37.
• Duff, K., & Paulsen, J. S. (2007). The influence of substance abuse on Huntington's disease. Journal of Neuropsychiatry and Clinical Neurosciences,
19(3), 365-372. [Link]
 61
Bibliography
• Frick, P. J., & Viding, E. (2009). Antisocial behavior from a developmental psychopathology perspective. Development and Psychopathology, 21(4),
1111-1133. [Link]
• Friedman, J. I., & Knable, M. B. (2008). Methamphetamine-induced neurotoxicity in Parkinson’s Disease: A review. Movement Disorders, 23(14),
2023-2030. [Link]
• Friedman, J. M., & Schofield, P. W. (2008). Methamphetamine abuse and Parkinson’s disease: Current understanding. Neurotoxicology and
Teratology, 30(5), 367-374. [Link]
• Frost, R. O., Krause, M. S., & Steketee, G. (2003). Cognitive-behavioral models of Obsessive-Compulsive Disorder: A review and update. Clinical
Psychology Review, 23(2), 181-208. [Link]
• Goldstein, R. Z., & Volkow, N. D. (2011). Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications. Nature
Reviews Neuroscience, 12(11), 733-743. [Link]
• Green, A. I., & Schmitz, J. M. (2008). Substance use disorders and schizophrenia: Cognitive deficits. Schizophrenia Research, 100(1-3), 185-191.
[Link]
• Greenfield, S. F., Back, S. E., & Brunette, M. F. (2010). Substance abuse and mental health disorders in women. Journal of Substance Abuse
Treatment, 38(4), 345-357.
• Gunderson, J. G. (2011). Borderline personality disorder. Guilford Press.
• Hardiman, O., & Al-Chalabi, A. (2011). The role of environmental and genetic factors in the pathogenesis of amyotrophic lateral sclerosis. Journal
of Neurology, Neurosurgery & Psychiatry, 82(6), 691-696. [Link]
• Harned, M. S., Lutz, C. R., & Torestad, R. (2012). Dialectical behavior therapy for borderline personality disorder. Journal of Clinical Psychology,
68(5), 518-531. [Link]
• Harper, C. (2009). Alcohol and the brain: Neuropathological consequences of alcoholism. Neuropsychology Review, 19(2), 203-217.
[Link]
• Harper, C. (2009). Alcohol and the brain: The latest research. British Journal of Pharmacology, 157(5), 676-688.
• Harris, A. H., & Smith, B. N. (2011). Prevention and early intervention strategies for substance use disorders. Substance Use & Misuse, 46(13),
1713-1724. [Link]
• Harris, M., & Fallot, R. D. (2001). Using trauma-informed care to enhance mental health services for trauma survivors. American Psychological
Association.
 62
Bibliography
• Insel, T. R. (2013). The NIMH research domain criteria (RDoC) project: Precision medicine for psychiatry. American Journal of Psychiatry, 170(4),
395-397. [Link]
• Jensen, P. S., & Hoagwood, K. E. (2014). Prevention and early intervention for mental health disorders. Psychiatric Services, 65(1), 44-52.
[Link]
• Jones, M., & Day, A. (2008). Substance use and its effects on health. Journal of Substance Use, 13(1), 1-14.
[Link]
• Jones, S., & Day, C. (2008). Substance use disorders and occupational impairment. Journal of Substance Abuse Treatment, 34(3), 236-249.
[Link]
• Kalapatapu, R. K., & Schmitz, J. M. (2007). Cognitive impairment and substance abuse. Journal of Neuropsychiatry and Clinical Neurosciences,
19(3), 339-345. [Link]
• Kalaria, R. N. (2010). Vascular basis for dementia. Frontiers in Aging Neuroscience, 2, 2. [Link]
• Kalivas, P. W. (2009). The glutamate homeostasis hypothesis of addiction. Nature Reviews Neuroscience, 10(8), 561-572.
[Link]
• Kalivas, P. W., & O’Brien, C. P. (2008). Drug addiction and the brain: The neurobiology of addiction. Scientific American, 298(2), 78-85.
[Link]
• Kaskutas, L. A. (2009). Alcoholics Anonymous effectiveness: A systematic review. Alcohol Research & Health, 32(1), 1-15.
• Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale for Schizophrenia. Schizophrenia Bulletin, 13(2), 261-276.
[Link]
• Kelly, J. F., Saitz, R., & Wakeman, S. E. (2016). Language and stigma: The role of terms in addiction treatment and recovery. Journal of Substance
Abuse Treatment, 66, 5-11. [Link]
• Kessler, R. C., & Wang, P. S. (2003). The epidemiology of mental disorders and the need for integrated care. Psychiatric Clinics of North America,
26(3), 583-605. [Link]
• Kollins, S. H. (2008). Impulsivity and substance abuse: Implications for treatment. In R. A. Johnson & M. W. Craighead (Eds.), Handbook of
depression (pp. 202-217). Guilford Press.
• Koob, G. F. (2015). Theoretical frameworks and animal models for addiction. Neuropsychopharmacology, 40(1), 16-23.
[Link]
 63
Bibliography
• Lechevallier-Michel, N., Mondon, K., & Olfson, M. (2005). Polypharmacy and the elderly. Current Opinion in Psychiatry, 18(4), 378-382.
[Link]
• Linehan, M. M. (1993). Cognitive-behavioral treatment of borderline personality disorder. Guilford Press.
• Marlatt, G. A., & Donovan, D. M. (2005). Relapse prevention: Maintenance strategies in the treatment of addictive behaviors. Guilford Press.
• McElroy, S. L., & Keck, P. E. (2001). Bipolar disorder and substance use. Journal of Clinical Psychiatry, 62(2), 82-90.
[Link]
• McFarlane, A. C. (2001). The relationship between trauma and post-traumatic stress disorder in adolescents. Journal of Trauma and Stress, 14(2),
357-367. [Link]
• McKay, J. R. (2009). Continuing care for alcohol and drug problems: A review of the evidence. Journal of Substance Abuse Treatment, 36(2), 116-
129. [Link]
• McLellan, A. T., Lewis, D. C., O’Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: Implications for treatment,
insurance, and outcomes evaluation. JAMA, 284(13), 1689-1695. [Link]
• McPartland, J. C., & Klin, A. (2012). Autism Spectrum Disorder and substance abuse: Interactions and clinical implications. Journal of Autism and
Developmental Disorders, 42(2), 341-350. [Link]
• Miller, A. L., & Campbell, J. L. (2008). Narcissistic Personality Disorder and substance abuse. Journal of Personality Disorders, 22(4), 328-342.
[Link]
• National Mental Health Institute (NMIH). (2019). Stimulant-induced paranoia: Clinical implications and management strategies. Journal of Mental
Health Disorders, 45(2), 231-240.
• National Mental Health Institute (NMIH). (2020). Cognitive impairments and grooming decline in alcohol-related neurocognitive disorders. National
Journal of Clinical Psychiatry, 39(1), 115-123.
• National Mental Health Institute (NMIH). (2021). Differentiating substance-induced hallucinations from primary psychotic disorders. Psychiatric
Research Quarterly, 47(3), 325-338.
• National Mental Health Institute (NMIH). (2022). Dual diagnosis: Managing comorbid substance use and personality disorders. National Journal of
Clinical Psychiatry, 52(1), 201-215.
 64
Bibliography
• National Mental Health Institute (NMIH). (2023). Stimulant-induced mania vs. bipolar mania: A comparative study. National Mental Health Institute
Journal, 51(4), 78-89.
• Nederhof, E., & Ormel, J. (2011). The impact of substance use on impulsivity in youth with Conduct Disorder. Journal of Child Psychology and
Psychiatry, 52(4), 425-432.[Link]
• Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with comorbid substance use disorders. Biological Psychiatry, 56(10), 778-
788. [Link]
• Peirce, J. M., Stitzer, M. L., & Bigelow, G. E. (2006). Contingency management for treatment of substance use disorders. Journal of Substance
Abuse Treatment, 30(2), 101-111. [Link]
• Perkins, D. O., & Finkelstein, D. (2013). Cocaine use and bipolar disorder: A review. Journal of Dual Diagnosis, 9(3), 277-288.
[Link]
• Pfefferbaum, A., & Sullivan, E. V. (1998). Alcohol and the brain: Neuroanatomy and neuroimaging. Neuropsychology Review, 8(3), 211-228.
[Link]
• Pittenger, C., & Bloch, M. H. (2011). The relationship between Obsessive-Compulsive Disorder and substance abuse: A review. Journal of Clinical
Psychiatry, 72(5), 522-529. [Link]
• Pope, H. G., & Brooks, J. M. (2015). Substance use and Alzheimer's disease: A review. Current Alzheimer Research, 12(5), 469-478.
[Link]
• Powers, M. B., Zumbo, B. D., & Murtagh, M. A. (2011). Crisis intervention for individuals with serious mental illness: A review of the literature.
Behavioral Health, 37(2), 23-32. [Link]
• Prochaska, J. O., & DiClemente, C. C. (1983). Stages and processes of self-change in smoking: Toward an integrative model of change. Journal of
Consulting and Clinical Psychology, 51(3), 390-395. [Link]
• Read, J., van Os, J., & Morrison, A. P. (2005). The role of trauma in psychosis: A review of the literature. Clinical Psychology Review, 25(4), 467-485.
• Regier, D. A., Farmer, M. E., & Rae, D. S. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American
Medical Association, 264(19), 2511-2518.
• Ribisl, K. M., Barlow, S. H., & Schaefer, A. L. (1997). The impact of alcohol use on social functioning in Avoidant Personality Disorder. Journal of
Clinical Psychiatry, 58(8), 322-329. [Link]
 65
Bibliography
• Stein, M. B., & Oathes, D. J. (2007). Cognitive control and perfectionism in Obsessive-Compulsive Personality Disorder. Biological Psychiatry, 61(2),
144-151. [Link]
• Steinberg, L. (2008). A social neuroscience perspective on adolescent risk-taking.
• Sue, S., & Sue, D. W. (2012). Counseling the culturally diverse: Theory and practice (6th ed.). Wiley.
• Sullivan, M. A., & Tetrault, J. M. (2007). Alcohol use disorder and depression: The dual burden. Addiction, 102(11), 1917-1924.
[Link]
• Swendsen, J. D., Conway, K. P., & Degenhardt, L. (2010). Substance use and mental disorders: Results from the National Comorbidity Survey.
American Journal of Psychiatry, 167(8), 890-897.
• Tolin, D. F. (2010). Assessment of posttraumatic stress disorder in children and adolescents. Clinical Psychology Review, 30(3), 290-298.
[Link]
• Vaillant, G. E. (2003). The natural history of alcoholism. Harvard University Press.
• Verma, S., Sharma, T., & Singh, S. (2018). Cognitive impairment in schizophrenia: Role of substance use. Schizophrenia Research, 193, 96-102.
• Victor, M., Adams, R. D., & Collins, G. H. (1989). The Wernicke-Korsakoff syndrome: Diagnosis and management. Neurology, 39(3), 354-362.
[Link]
• Vogel, D. L., Wade, N. G., & Hackler, A. H. (2007). Perceived stigma and mental health treatment seeking. Journal of Mental Health, 16(3), 265-
273. [Link]
• Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of
Medicine, 374(4), 363-371. [Link]
• Volkow, N. D., Michaelides, M., & Baler, R. D. (2017). The neuroscience of drug addiction: Implications for treatment. Science, 356(6337), 202-207.
[Link]
• Wagner, T. H., & Burns, R. M. (2007). The role of case management in the treatment of substance use disorders. Journal of Substance Abuse
Treatment, 33(3), 227-234. [Link]
• Wechsler, D. (2008). Wechsler Adult Intelligence Scale (WAIS-IV). Pearson.
• Zhou, X., Li, X., & Lee, T. (2015). Mobile health technologies for monitoring and managing chronic diseases: A review. Journal of Medical Internet
Research, 17(3), e64. [Link]